Loading...
XNYS
WAT
Market cap42bUSD
Oct 08, Last price  
429.13USD
1D
-1.57%
1Q
14.00%
Jan 2017
219.32%
Name

Waters Corp

Chart & performance

D1W1MN
XNYS:WAT chart
P/E
65.57
P/S
13.31
EPS
6.55
Div yield, %
—
Shrs. gr., 5y
-0.88%
Rev. gr., 5y
6.00%
Revenues
3.17b
+6.99%
1,280,229,0001,473,048,0001,575,124,0001,498,700,0001,643,371,0001,851,184,0001,843,641,0001,904,218,0001,989,344,0002,042,332,0002,167,423,0002,309,078,0002,419,929,0002,406,596,0002,365,365,0002,785,874,0002,971,956,0002,956,416,0002,958,387,0003,165,286,000
Net income
643m
+0.75%
222,200,000268,072,000322,479,000323,313,000381,763,000432,968,000461,443,000450,003,000431,620,000469,053,000521,503,00020,311,000593,794,000592,198,000521,571,000692,843,000707,755,000642,234,000637,834,000642,629,000
CFO
653m
-14.38%
263,594,000370,507,000418,248,000418,263,000457,856,000497,374,000449,280,000484,876,000511,648,000560,293,000629,076,000697,640,000604,446,000643,087,000790,507,000747,274,000611,661,000602,809,000762,123,000652,555,000
Dividend
Nov 26, 19960.16 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Waters Corporation is a global leader in specialized measurement, delivering analytical solutions across Asia, the Americas, and Europe. The company operates through two main divisions: Waters and TA. Under its Waters segment, it engineers, manufactures, sells, and provides support for high and ultra-performance liquid chromatography and mass spectrometry (MS) systems. This includes essential consumables like chromatography columns and comprehensive post-warranty service plans. The TA segment focuses on designing, producing, selling, and servicing instruments for thermal analysis, rheometry, and calorimetry. Additionally, Waters develops and supplies sophisticated software that integrates with both its own instruments and those from other manufacturers. The company's advanced MS technology plays a crucial role in various applications, such as drug discovery and development (including clinical trial assessments), analyzing proteins involved in disease processes, ensuring nutritional safety, and conducting environmental testing. Its thermal analysis, rheometry, and calorimetry instruments are vital for assessing the suitability and stability of a wide range of materials, including fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids. These instruments support diverse sectors like industrial manufacturing, consumer goods, healthcare products, and life science research. Waters' extensive client base spans the life sciences, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental sectors, where its products are instrumental in research and development, quality assurance, and general laboratory operations. Established in 1958, Waters Corporation is headquartered in Milford, Massachusetts.

Related entities

Subsidiaries
WATERS PACIFIC PTE. LTD.

Key people

Independent Chairman of the Board · since 2020
President, Chief Executive Officer, Director · since 2020
Jianqing Bennett
Senior Vice President - TA Instruments Division and Clinical Business Unit · since 2021
Robert Carpio
Senior Vice President - Waters Division · since 2024
Amol Chaubal
Chief Financial Officer, Senior Vice President · since 2021
William Curry
Vice President, Principal Accounting Officer, Corporate Controller · since 2011
Independent Director · since 2018
Independent Director · since 2022
Independent Director · since 2023
Pearl Huang
Independent Director · since 2021
Heather Knight
Independent Director · since 2024
Christopher Kuebler
Independent Director · since 2006
Independent Director · since 2022
Jiang Wei
Independent Director · since 2021
IPO date
Nov 17, 1995
Employees
8,200
Domiciled in
US
Incorporated in
US
Legal address
CORPORATION TRUST CENTER 1209 ORANGE ST
WILMINGTON, DE 19801
US
Headquarters
34 Maple Street
Milford, MA 01757
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT